More Action Against Novartis As Korea FTC Issues Fine For Unfair Promotion
Executive Summary
In another blow to Novartis, South Korea's Fair Trade Commission has imposed a fine on the South Korean subsidiary of the Swiss firm for carrying out unfair promotion of its products at meetings for medical professionals.
You may also be interested in...
Dong-A Faces Price Hit As Korea Ups Fight Against Illegal Rebates
In its ongoing clamp down against illegal rebate activities in the domestic pharmaceutical industry, South Korea cuts prices of Dong-A ST’s drugs. This follows recent punitive measures against Novartis' Korean subsidiary.
Novartis Slapped With New $49m Fine For Korea ‘Rebates’
Novartis's South Korean subsidiary has been hit with a new fine of around $49m and reimbursement suspensions for a number of its drugs under a new ministerial action related to illegal "rebate" payments made to prescribers.
Deal Watch: Chinook To Go Public Via Reverse Merger With Troubled Aduro
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Need a specific report? 1000+ reports available
Buy Reports